Abstract 4127: Niraparib is active against prostate xenograft models that are wild type or defective for DNA damage repair genes
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-4127
Abstract: Patients with metastatic prostate cancer may respond well to first- and second-generation androgen receptor (AR)-targeted therapies, but all will eventually experience disease progression, indicating a need for alternative therapies. A subset of these patients bears… read more here.
Keywords: prostate; xenograft models; cancer; prostate xenograft ... See more keywords